Questcor plummets after Aetna slashes insurance coverage for most Acthar uses
This article was originally published in Scrip
Questcor Pharmaceuticals' stock price was cut nearly in half - falling 47.8% from $50.52 per share on 18 September to $26.35 at market close on 19 September - in response to US health insurance company Aetna's decision to drop coverage for all but one of the 19 approved indications for HP Acthar gel (repository corticotropin injection).
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.